TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22166557
Drug: Balapiravir 500,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Balapiravir 500, 1000, or 1500 mg twice daily plus peginterferon alfa-2a (40KD)/ribavirin
Study: 22166557
Drug: Balapiravir/peginterferon alfa-2a/ribavirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Balapiravir/peginterferon alfa-2a/ribavirin combination
Study: 20531106
Drug: Enema Casen
Normalized name: caseins
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enema Casen (250 ml)
Study: 20531106
Drug: Fleet Enema
Normalized name: Fleet Enema
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fleet Enema (133 ml)
Study: 18549372
Drug: In-clinic rescue
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: In-clinic rescue therapy (maximum of 2 visits per month)
Study: 18549372
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (optimal self‐administered medical therapy)
Study: 18549372
Drug: In-clinic rescue
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: In-clinic rescue therapy
Study: 15909441
Drug: Zinc paste
Normalized name: ZINC PASTE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc paste compound
Study: 12543286
Drug: Elevated chromogranin
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elevated chromogranin A level (cutoff, 24 ng/mL)
Study: 31129930
Drug: ASP2205 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASP2205 10 mg
Study: 31129930
Drug: ASP2205 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASP2205 60 mg
Study: 24108780
Drug: EV71 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: EV71 vaccine (400 U of EV71 antigen)
Study: 15592213
Drug: Bionator therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bionator therapy
Study: 11115338
Drug: Bile leakage
Normalized name: bile salts
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bile leakage test (injection of isotonic sodium chloride solution through the cystic duct)
Study: 7662225
Drug: bisoprolol (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: bisoprolol (10 mg/day)
Study: 7662225
Drug: verapamil SR
Normalized name: Dom-Verapamil SR
DrugBank: Verapamil (DB00661)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: verapamil SR (240 mg/day)
Study: 322827
Drug: Live-attenuated A/Hong
Approvals — FDA: no, EMA: no, PMDA: no
Description: Live-attenuated A/Hong Kong/68 (H3N2) influenza vaccine
Study: 31977858
Drug: Vicagrel 40
Normalized name: Vicagrel
DrugBank: Vicagrel (DB16349)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vicagrel 40 to 75 mg
Study: 28187226
Drug: Calcifediol (25D3)
Normalized name: Calcifediol
DrugBank: Calcifediol (DB00146)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcifediol (25D3) 20 μg/d
Study: 21755327
Drug: n‐3 PUFA‐enriched
Approvals — FDA: no, EMA: no, PMDA: no
Description: n‐3 PUFA‐enriched tomato juice (500 mL daily, providing 250 mg of EPA and DHA)
Study: 17582564
Drug: Ty21a live
Normalized name: Salmonella typhi Ty21a live antigen
DrugBank: Typhoid Vaccine Live (DB11050)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ty21a live oral typhoid vaccine (2 doses in Norte, 3 doses in Occidente)
Study: 17582564
Drug: Ty21a live
Normalized name: Salmonella typhi Ty21a live antigen
DrugBank: Typhoid Vaccine Live (DB11050)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ty21a live oral typhoid vaccine (pooled analysis)
Study: 11588454
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg iv omeprazole bolus injection (arm I)
Study: 11588454
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg bolus followed by 8 mg/hr continuous infusion (arm II)
Study: 31693299
Drug: Differential fractional
Normalized name: LIVER FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Differential fractional excretion of sodium (FeNa) derived from a morning void collection
Study: 27584715
Drug: Matrix therapy
Normalized name: Matrix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matrix therapy agent (ReGeneraTing Agent [RGTA])
Study: 21652150
Drug: Intranasal spray
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal spray of oxytocin
Study: 16245966
Drug: Brinzolamide twice-daily
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Brinzolamide twice-daily
Study: 16245966
Drug: Dorzolamide three
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dorzolamide three times daily (Control)
Study: 12076696
Drug: Fluconazole 50
Normalized name: fluconazole 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluconazole 50 mg once daily for 7-14 days
Study: 12076696
Drug: Amphotericin B
Normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amphotericin B 0.5 g thrice daily for 7-14 days
Study: 9527195
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of 30 g alpha‐KG/hour after the operation
Study: 7608318
Drug: Eptastigmine 10
Normalized name: Rivastigmine
DrugBank: Rivastigmine (DB00989)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Eptastigmine 10 mg
Study: 7608318
Drug: Eptastigmine 30
Normalized name: Rivastigmine
DrugBank: Rivastigmine (DB00989)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Eptastigmine 30 mg
Study: 2187791
Drug: Sulphaphenazole 1
Normalized name: Sulphathiazole
DrugBank: Sulfathiazole (DB06147)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sulphaphenazole 1 g 12 hourly by mouth x 10 days
Study: 2187791
Drug: Inj streptomycin
Normalized name: streptomycin Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inj streptomycin 1 g intramuscularly daily with sulphaphenazole 1 g 12 hourly orally x 10 days
Study: 2187791
Drug: trimethoprim 200
Normalized name: trimethoprim 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: trimethoprim 200 mg 12 hourly by mouth x 7‐10 days
Study: 2187791
Drug: erythromycin 500
Normalized name: erythromycin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: erythromycin 500 mg 6 hourly orally x 7‐10 days
Study: 30813125
Drug: Conventional pulmonary
Normalized name: Lobaria pulmonaria extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional pulmonary rehabilitation treatments (pursed lips breathing and abdominal breathing training)
Study: 26125924
Drug: Conventional perioperative
Normalized name: ENSURE SURGERY PERIOPERATIVE KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional perioperative treatment
Study: 23414174
Drug: Personal Concerns
Approvals — FDA: no, EMA: no, PMDA: no
Description: Personal Concerns Inventory plus treatment as usual
Study: 21717884
Drug: Travoprost 0.004%/Timolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Travoprost 0.004%/Timolol 0.5% fixed combination
Study: 21717884
Drug: Latanoprost 0.005%/Timolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Latanoprost 0.005%/Timolol 0.5% fixed combination
Study: 21717884
Drug: Timolol 0.5%
Normalized name: Timolol 0.5% Ophthalmic Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Timolol 0.5% twice a day
Study: 19366826
Drug: Cetuximab (Erbitux)
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Cetuximab (Erbitux) in monotherapy or in combination with irinotecan
Study: 15014018
Drug: High-dose IFN-alpha
Normalized name: IFN .ALPHA.-1B
DrugBank: Interferon alfa-1b (DB18522)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose IFN-alpha 2b (HDI)
Study: 11245347
Drug: Associated administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Associated administration
Study: 9758295
Drug: Cerebrospinal fluid
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cerebrospinal fluid magnesium (CSF Mg+2) levels
Study: 9758295
Drug: Serum magnesium
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum magnesium (serum Mg+2) levels
Study: 7805677
Drug: Mean power
Normalized name: guaifenesin
DrugBank: Guaifenesin (DB00874)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mean power at 4 mmol.l-1 [la-]b
Study: 2647819
Drug: Albuterol aerosol
Normalized name: Albuterol Inhalation Aerosol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol aerosol (180 micrograms, four times a day)
Study: 2647819
Drug: Albuterol powder
Normalized name: albuterol Inhalation Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol powder (200 micrograms, four times a day)
Study: 26467414
Drug: Adjunctive omega-3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunctive omega-3 fatty acid supplementation
Study: 26467414
Drug: Adjunctive omega-3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunctive omega-3 fatty acids
Study: 21932934
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of IPL and radio frequency (RF)
Study: 18242894
Drug: Topical DHEA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical DHEA (1%)
Study: 14640494
Drug: SP plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: SP plus paracetamol
Study: 8855148
Drug: Bisphosphonate treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bisphosphonate treatment (various doses)
Study: 1610422
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg ranitidine
Study: 24345793
Drug: Levothyroxine (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levothyroxine (300 μg/d)
Study: 18595436
Drug: Mifepristone (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mifepristone (600 mg for 5 days)
Study: 11863118
Drug: Oral etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral etoposide 50 mg/m2 for 21 consecutive days every 4 weeks for three courses
Study: 11863118
Drug: No further
Approvals — FDA: no, EMA: no, PMDA: no
Description: No further therapy (observation)
Study: 27053275
Drug: Antipsychotic drugs
Normalized name: Diazepines, oxazepines, thiazepines and oxepines antipsychotic drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antipsychotic drugs (AP)
Study: 2076391
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg nifedipine/day
Study: 7030354
Drug: GABA (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: GABA (12 tablets, 3 g daily for 8 weeks)
Study: 7030354
Drug: Pyrithioxine (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pyrithioxine (3 tablets, 600 mg daily for 8 weeks)
Study: 30761961
Drug: Whole grain
Normalized name: Whole grain barley
DrugBank: Barley (DB10506)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole grain diet (120 g of bread made with whole flour daily)
Study: 25529309
Drug: Extended haemodialysis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended haemodialysis (≥24 h weekly)
Study: 25529309
Drug: Standard haemodialysis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard haemodialysis (12-18 h weekly)
Study: 22143010
Drug: Fentanyl 50
Normalized name: fentanyl 50 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl 50 μg and propofol 0.5 mg/kg (group P)
Study: 22143010
Drug: Fentanyl 50
Normalized name: fentanyl 50 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl 50 μg and etomidate 0.1 mg/kg (group E)
Study: 17182429
Drug: Strengths Oriented
Approvals — FDA: no, EMA: no, PMDA: no
Description: Strengths Oriented Family Therapy (SOFT)
Study: 8370866
Drug: Short-term psychological
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term psychological treatments
Study: 29533038
Drug: Arthroscopy-guided core
Normalized name: diclofenac
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Arthroscopy-guided core decompression and bone grafting combined with selective arterial infusion
Study: 29533038
Drug: Percutaneous core
Approvals — FDA: no, EMA: no, PMDA: no
Description: Percutaneous core decompression combined with selective arterial infusion
Study: 26254196
Drug: Palmaria palmata-enriched
Normalized name: PALMARIA PALMATA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palmaria palmata-enriched bread (5 g/day)
Study: 16803603
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment (omeprazole, amoxicillin, and clarithromycin)
Study: 14709953
Drug: Modafinil (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modafinil (100 to 400 mg/d for 4 weeks)
Study: 11281824
Drug: Neuroprotective agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neuroprotective agents (specific agents not mentioned)
Study: 8142099
Drug: 1.5% lidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5% lidocaine with epinephrine 3.75 micrograms/ml (Group A)
Study: 8142099
Drug: 2% lidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% lidocaine with epinephrine 5 micrograms/ml (Group B)
Study: 3147196
Drug: Sodium cromoglycate
Normalized name: Sodium cromoglycate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium cromoglycate inhaled at maximum flow rate (V1)
Study: 3147196
Drug: Sodium cromoglycate
Normalized name: Sodium cromoglycate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium cromoglycate inhaled at 100 l.min‐1 (V2)
Study: 3147196
Drug: Sodium cromoglycate
Normalized name: Sodium cromoglycate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium cromoglycate inhaled at 50 l.min‐1 (V3)
Study: 29951734
Drug: Umeclidinium/Vilanterol (UMEC/VI)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Umeclidinium/Vilanterol (UMEC/VI) 62.5/25 µg
Study: 23992191
Drug: Misoprostol (doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Misoprostol (doses not specified)
Study: 20406224
Drug: Rupatadine 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rupatadine 100 mg
Study: 12660685
Drug: Sarpogrelate in
Normalized name: Sarpogrelate
DrugBank: Sarpogrelate (DB12163)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sarpogrelate in addition to aspirin and ticlopidine
Study: 30284585
Drug: Remifentanil (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil (1 μg/kg prior to induction, 0.05-0.5 μg/kg/minute during maintenance)
Study: 30284585
Drug: Dexmedetomidine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (1 μg/kg prior to induction, 0.2-0.7 μg/kg/hour during maintenance)
Study: 18547903
Drug: Once-daily regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily regimen of efavirenz, extended-release stavudine, and lamivudine (QD arm)
Study: 18547903
Drug: Existing therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Existing therapy (BID+ arm)
Study: 12849809
Drug: Subcutaneous administration
Normalized name: subcutaneous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous administration of 300 IU rFSH
Study: 12849809
Drug: Intramuscular administration
Normalized name: Japanese Encephalitis vaccine for intramuscular administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular administration of 300 IU rFSH
Study: 9032569
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no therapy other than calcium)
Study: 2007040
Drug: Midazolam (4.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (4.2 +/- 1.4 mg loading dose; 8.6 +/- 5.4 mg/h maintenance infusion)
Study: 2007040
Drug: Propofol (69
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (69 +/- 23 mg loading dose; 265 +/- 185 mg/h maintenance infusion)
Study: 6812849
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of 1200 mg flumequine orally
Study: 6812849
Drug: Two-dose regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-dose regimen of 1200 and 800 mg flumequine
Study: 6812849
Drug: Three-dose regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three-dose regimen of 1200, 800, and 800 mg flumequine (six hours apart)
Study: 30874754
Drug: Antiarrhythmic medication
Normalized name: ANTIARRHYTHMICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiarrhythmic medication (n=76)
Study: 24601726
Drug: High fructose
Normalized name: High Fructose Corn Syrup
Approvals — FDA: no, EMA: no, PMDA: no
Description: High fructose (HF; 80 g/d)
Study: 24601726
Drug: Medium fructose
Normalized name: Fructose
DrugBank: Fructose (DB04173)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Medium fructose (MF; 40 g/d)
Study: 24601726
Drug: High sucrose
Normalized name: Sucrose
DrugBank: Sucrose (DB02772)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High sucrose (HS; 80 g/d)
Study: 24601726
Drug: High glucose
Normalized name: ONE TOUCH HIGH GLUCOSE CONTROL SOLN
Approvals — FDA: no, EMA: no, PMDA: no
Description: High glucose (HG; 80 g/d)
Study: 17461312
Drug: Immunonutrition group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunonutrition group (oral supplementation for five days before and five days after surgery with 900 mL/day of a formula enriched with arginine, gamma‐3‐fatty acid and RNA + liquid diet ad libitum on one and two postoperative day and then solid food)
Study: 17461312
Drug: Conventional group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional group (no artificial nutrition before and after surgery, on one and two postoperative day intravenous solution of 5% glucose and electrolytes and then normal diet)
Study: 15214299
Drug: Calcium 0.5
Normalized name: CALCIUM 0.55 ORAL TABLET [Restoration Treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium 0.5 g/d and placebo
Study: 8822046
Drug: Erythromycin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin (500 mg t.i.d. for one week)
Study: 1456855
Drug: Calcium carbonate
Normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium carbonate (9.98 mmol [400 mg] of elemental calcium) three times daily with meals for 6 weeks
Study: 6390462
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg nicotinic acid alone per day for 30 days
Study: 6390462
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg nicotinic acid plus 60,000 U retinol and 140 mg tocopherols per day for 30 days
Study: 23937282
Drug: Amitriptyline or
Normalized name: amitriptyline Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline or Nortriptyline (as monotherapy or adjuvant therapy)
Study: 15888513
Drug: Antipsychotic exposed
Normalized name: lactose, x-ray exposed (1000 rad)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antipsychotic exposed (< 12 weeks)
Study: 12766094
Drug: nateglinide (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: nateglinide (120 mg a.c.) added to rosiglitazone monotherapy (8 mg q.d.)
Study: 12766094
Drug: placebo added
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo added to rosiglitazone monotherapy
Study: 8918486
Drug: Concurrent cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Concurrent cisplatin 100 mg/m2 at 2-week intervals for three cycles with pelvic radiation
Study: 8918486
Drug: Radiation without
Normalized name: threonine
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Radiation without chemotherapy (Control)
Study: 29097225
Drug: Single-dose miconazole
Normalized name: Miconazole
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Single-dose miconazole suppository
Study: 29097225
Drug: Multiple-dose miconazole
Normalized name: Miconazole
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Multiple-dose miconazole suppository
Study: 29097225
Drug: Multiple-dose miconazole
Normalized name: Miconazole
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Multiple-dose miconazole cream
Study: 18630487
Drug: Preoperative immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative immunotherapy with IL-2 (12 MIU/day SC for 3 consecutive days)
Study: 18630487
Drug: Preoperative immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative immunotherapy with IL-2 plus surgery
Study: 16052765
Drug: Adper Prompt
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adper Prompt L-Pop/Z100 (3M ESPE)
Study: 12193491
Drug: Intrathecal sufentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal sufentanil 50 micro g and morphine 500 micro g
Study: 10063812
Drug: Creatine (C:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatine (C: 25 g X d(‐1) for 5 d)
Study: 7734252
Drug: Ephedrine alone
Normalized name: Ephedrine
DrugBank: Ephedrine (DB01364)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ephedrine alone (0.2 mg kg‐1 bolus followed by 0.5 mg kg‐1 h‐1 infusion)
Study: 7734252
Drug: Ephedrine and
Normalized name: Ephedrine and guaifenesin only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ephedrine and colloid (polygeline, Haemaccel) 8 ml kg‐1
Study: 1791077
Drug: Monotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monotherapy with cefotaxime
Study: 31245333
Drug: OtoClear® Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: OtoClear® Spray Wash Kit
Study: 19291114
Drug: Maggot debridement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maggot debridement therapy (MDT) with Lucilia cuprina
Study: 1633839
Drug: Conventional injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional injection of glucagon (1 mg)
Study: 1633839
Drug: Glucagon injection
Normalized name: glucagon Injection
DrugBank: Glucagon (DB00040)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Glucagon injection with CGRP (10 nmole)
Study: 1633839
Drug: Glucagon injection
Normalized name: glucagon Injection
DrugBank: Glucagon (DB00040)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Glucagon injection using a multihole 'sprinkler' needle
Study: 6405428
Drug: Intravenous d-amphetamine
Normalized name: amphetamine / dextroamphetamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous d-amphetamine sulphate (15 mg)
Study: 6405428
Drug: Oral d-amphetamine
Normalized name: amphetamine / dextroamphetamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral d-amphetamine sulphate (15 mg)
Study: 31492766
Drug: 1 ppm
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 ppm of EGF ointment
Study: 31492766
Drug: 20 ppm
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 ppm of EGF ointment
Study: 28079557
Drug: Dobutamine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dobutamine infusion (20 μg kg‐1 min‐1)